Search

Your search keyword '"Preudhomme, Claude"' showing total 1,778 results

Search Constraints

Start Over You searched for: Author "Preudhomme, Claude" Remove constraint Author: "Preudhomme, Claude"
1,778 results on '"Preudhomme, Claude"'

Search Results

51. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

52. Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia

55. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

56. Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia

57. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

59. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

60. Figure S1 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

61. Table S6 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

62. Supplementary Data from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

63. Data from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

64. Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

65. Supplemental Table 1 Gene expression profilling from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

66. Supplementary Table 1, Supplementary Figures 1-4 from TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

67. List of pathways analyzed for GSEA from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

68. Comprehensive mutational profiling of core binding factor acute myeloid leukemia

70. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

72. Prognostic impact of CEBPAmutational subgroups in adult AML

74. Cytogénétique hématologique

75. Cytologie

76. Groupes sanguins érythrocytaires

78. Exploration des proliférations myéloïdes

79. Exploration des pathologies érythrocytaires

80. Autres contextes clinico-biologiques

81. Anticorps anti-érythrocytaires

82. Exploration des anomalies de l’hémoglobine

83. Exploration des anomalies du métabolisme du fer et hémolyse

84. Autres techniques moléculaires

85. Maladie résiduelle moléculaire

87. Suivi biologique des traitements antithrombotiques

88. Cytométrie en flux

89. Tests globaux et facteurs de coagulation

90. Exploration des proliférations lymphoïdes

91. Annexes

92. Diagnostic d’exclusion de maladie thromboembolique veineuse

93. Autres anticorps anti-éléments figurés du sang

94. Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France.

96. Disease evolution and outcomes in familial AML with germline CEBPA mutations

98. Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

99. A 17-gene stemness score for rapid determination of risk in acute leukaemia

100. Real‐life challenges using personalized prognostic scoring systems in acute myeloid leukemia

Catalog

Books, media, physical & digital resources